IAM1363
Iambic's AI-Designed HER2 Drug IAM1363 Shows Durable Responses at ESMO 2026
Iambic Therapeutics has presented updated Phase 1/1b data for IAM1363, a selective, brain-penetrant HER2 tyrosine kinase inhibitor, showing durable anti-tumor activity…
Iambic files IND for IAM217, a brain-penetrant KIF18A inhibitor designed with AI
Iambic Therapeutics has submitted an Investigational New Drug application to the U.S. FDA for IAM217, a brain-penetrant inhibitor of KIF18A, to start a Phase 1/2 trial.…